TransAlta Corporation Ordinary Shares (TAC)

Total Costs & Expenses

$2.18B

TTM · Period ending: · CAD

TAC logo

TAC Total Costs & Expenses

Latest reported$2.18B CAD
TAC TTM Total Costs & Expenses · CAD ($0.00 → $2.18B)
High-resolution chart · PNG

TAC total costs & expenses history

Trailing twelve months (TTM) · CAD. Each value covers four complete reported quarters.

TransAlta Corporation Ordinary Shares Total Costs & Expenses — Trailing twelve months (TTM) (CAD)
Period endingTotal Costs & Expenses (CAD)
2,178,836,597
2,269,836,597
2,385,438,510
2,369,000,000
2,312,000,000
2,300,000,000
2,260,000,000
2,191,000,000
2,151,000,000
2,234,000,000
2,266,000,000
2,484,000,000
2,729,000,000
2,660,000,000
2,445,000,000
2,209,000,000
2,716,000,000
2,820,000,000
2,960,000,000
3,037,000,000
2,380,000,000
2,295,000,000
2,200,000,000
2,054,000,000
1,974,000,000
1,970,000,000
2,108,000,000
2,206,000,000
2,255,000,000
2,255,000,000
2,023,000,000
1,999,000,000
2,002,000,000
2,014,000,000
2,149,000,000
1,953,000,000
1,955,000,000
1,947,000,000
1,893,000,000
2,011,000,000
2,068,000,000
2,081,000,000
2,130,000,000
2,145,000,000
2,074,000,000
2,082,000,000
2,192,000,000
2,231,000,000
2,192,000,000
2,179,000,000
2,007,000,000
1,964,000,000
1,896,000,000
1,860,000,000
1,856,000,000
1,926,000,000
1,989,000,000
2,009,000,000
2,018,000,000
2,026,000,000
2,110,000,000
2,189,000,000
2,322,000,000
2,325,000,000
2,269,000,000
2,313,000,000
2,392,000,000
2,471,030,813
2,591,413,610
2,635,109,316
2,578,243,664
2,340,912,782
2,315,830,790
2,276,135,084
2,233,601,290
2,739,002,740
2,683,502,762
2,631,803,375
2,639,902,727
2,404,500,568
2,421,799,625
2,428,699,086
2,422,099,543
-653,798,863
-1,256,898,747
-1,787,098,821
-2,360,199,184
-1,972,701,276
-1,972,701,276
-1,972,701,276
-1,465,101,276
-1,018,699,969
-691,699,969
-408,799,969
-916,399,969
-3,938,299,618
-4,265,299,618
-4,548,199,618
-3,917,199,618
2,311,799,280
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.